BG108071A - Есенциални мастни n-3-киселини в лечението на сърдечна недостатъчност и сърдечна слабост - Google Patents

Есенциални мастни n-3-киселини в лечението на сърдечна недостатъчност и сърдечна слабост Download PDF

Info

Publication number: BG108071A
Authority: BG; Bulgaria
Prior art keywords: heart failure; epa; dha; use according; mixture
Prior art date: 2001-01-25

Application number

BG108071A

Other languages

Bulgarian (bg)

English (en)

Inventor

Francesco Granata

Franco Pamparana

Eduardo Stragliotto

Original Assignee

Pharmacia Italia S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-25

Filing date

2003-08-07

Publication date

2005-04-30

2003-08-07 Application filed by Pharmacia Italia S.P.A. filed Critical Pharmacia Italia S.P.A.

2005-04-30 Publication of BG108071A publication Critical patent/BG108071A/bg

Links

206010019280 Heart failures Diseases 0.000 title claims abstract description 40
235000020660 omega-3 fatty acid Nutrition 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 37
235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 37
229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 36
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 36
MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 33
239000003814 drug Substances 0.000 claims abstract description 29
235000004626 essential fatty acids Nutrition 0.000 claims abstract description 21
239000000203 mixture Substances 0.000 claims abstract description 20
238000011282 treatment Methods 0.000 claims abstract description 20
229940124597 therapeutic agent Drugs 0.000 claims abstract description 18
208000019622 heart disease Diseases 0.000 claims abstract description 13
230000002265 prevention Effects 0.000 claims abstract description 13
125000004494 ethyl ester group Chemical group 0.000 claims abstract description 7
230000001154 acute effect Effects 0.000 claims description 10
230000001684 chronic effect Effects 0.000 claims description 10
239000005541 ACE inhibitor Substances 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 6
239000003112 inhibitor Substances 0.000 claims description 6
229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 5
SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
-1 visoprolol Chemical compound 0.000 claims description 5
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 4
WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 4
238000011284 combination treatment Methods 0.000 claims description 4
229960000648 digitoxin Drugs 0.000 claims description 4
WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 claims description 4
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 4
108010064733 Angiotensins Proteins 0.000 claims description 3
102000015427 Angiotensins Human genes 0.000 claims description 3
108010061435 Enalapril Proteins 0.000 claims description 3
229960003304 acetyldigoxin Drugs 0.000 claims description 3
HWKJSYYYURVNQU-DXJNJSHLSA-N acetyldigoxin Chemical compound C1[C@H](OC(C)=O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O HWKJSYYYURVNQU-DXJNJSHLSA-N 0.000 claims description 3
MGVYFNHJWXJYBE-UHFFFAOYSA-N alpha-Acetyl-digoxin Natural products CC1OC(CC(O)C1O)OC2C(O)CC(OC3C(C)OC(CC3OC(=O)C)OC4CCC5(C)C(CCC6C5CCC7(C)C(C(O)CC67O)C8=CC(=O)OC8)C4)OC2C MGVYFNHJWXJYBE-UHFFFAOYSA-N 0.000 claims description 3
239000002876 beta blocker Substances 0.000 claims description 3
229940097320 beta blocking agent Drugs 0.000 claims description 3
229960000830 captopril Drugs 0.000 claims description 3
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 3
229960004195 carvedilol Drugs 0.000 claims description 3
NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims description 3
229960005025 cilazapril Drugs 0.000 claims description 3
HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 claims description 3
238000002648 combination therapy Methods 0.000 claims description 3
208000035475 disorder Diseases 0.000 claims description 3
239000002934 diuretic Substances 0.000 claims description 3
229940030606 diuretics Drugs 0.000 claims description 3
229960000873 enalapril Drugs 0.000 claims description 3
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 3
229960003883 furosemide Drugs 0.000 claims description 3
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 3
229960002003 hydrochlorothiazide Drugs 0.000 claims description 3
239000004041 inotropic agent Substances 0.000 claims description 3
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 3
229960002237 metoprolol Drugs 0.000 claims description 3
208000010125 myocardial infarction Diseases 0.000 claims description 3
229960002164 pimobendan Drugs 0.000 claims description 3
GLBJJMFZWDBELO-UHFFFAOYSA-N pimobendane Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2N1 GLBJJMFZWDBELO-UHFFFAOYSA-N 0.000 claims description 3
229940124549 vasodilator Drugs 0.000 claims description 3
239000003071 vasodilator agent Substances 0.000 claims description 3
239000002083 C09CA01 - Losartan Substances 0.000 claims description 2
239000004072 C09CA03 - Valsartan Substances 0.000 claims description 2
239000002053 C09CA06 - Candesartan Substances 0.000 claims description 2
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 2
229960000932 candesartan Drugs 0.000 claims description 2
SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims description 2
230000003130 cardiopathic effect Effects 0.000 claims description 2
150000001875 compounds Chemical class 0.000 claims description 2
229940082657 digitalis glycosides Drugs 0.000 claims description 2
229960005156 digoxin Drugs 0.000 claims description 2
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 2
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 2
229960003638 dopamine Drugs 0.000 claims description 2
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims description 2
229960000201 isosorbide dinitrate Drugs 0.000 claims description 2
229960004773 losartan Drugs 0.000 claims description 2
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 2
229960003746 metildigoxin Drugs 0.000 claims description 2
IYJMSDVSVHDVGT-PEQKVOOWSA-N metildigoxin Chemical compound O1[C@H](C)[C@@H](OC)[C@@H](O)C[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O IYJMSDVSVHDVGT-PEQKVOOWSA-N 0.000 claims description 2
LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 claims description 2
229960004699 valsartan Drugs 0.000 claims description 2
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 2
LPUDGHQMOAHMMF-JBACZVJFSA-N (2s)-2-[[[(2s)-6-amino-2-(methanesulfonamido)hexanoyl]amino]methyl]-3-[1-[[(1s)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]cyclopentyl]propanoic acid Chemical compound N([C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)C1(C[C@@H](CNC(=O)[C@H](CCCCN)NS(=O)(=O)C)C(O)=O)CCCC1 LPUDGHQMOAHMMF-JBACZVJFSA-N 0.000 claims 1
229950000973 omapatrilat Drugs 0.000 claims 1
229950001780 sampatrilat Drugs 0.000 claims 1
238000000034 method Methods 0.000 abstract description 10
230000001225 therapeutic effect Effects 0.000 abstract description 7
TYLNXKAVUJJPMU-DNKOKRCQSA-N Docosahexaenoic acid ethyl ester Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(=O)OCC TYLNXKAVUJJPMU-DNKOKRCQSA-N 0.000 abstract 2
235000020669 docosahexaenoic acid Nutrition 0.000 abstract 1
239000002775 capsule Substances 0.000 description 10
230000000747 cardiac effect Effects 0.000 description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
229940079593 drug Drugs 0.000 description 5
201000010099 disease Diseases 0.000 description 4
238000005086 pumping Methods 0.000 description 4
230000006378 damage Effects 0.000 description 3
230000004064 dysfunction Effects 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
230000000750 progressive effect Effects 0.000 description 3
102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
102000002723 Atrial Natriuretic Factor Human genes 0.000 description 2
101800001288 Atrial natriuretic factor Proteins 0.000 description 2
101800001890 Atrial natriuretic peptide Proteins 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
241000208011 Digitalis Species 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
229960002105 amrinone Drugs 0.000 description 2
RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 2
229960002781 bisoprolol Drugs 0.000 description 2
VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 2
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
WMVRXDZNYVJBAH-UHFFFAOYSA-N dioxoiron Chemical compound O=[Fe]=O WMVRXDZNYVJBAH-UHFFFAOYSA-N 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
229960000972 enoximone Drugs 0.000 description 2
ZJKNESGOIKRXQY-UHFFFAOYSA-N enoximone Chemical compound C1=CC(SC)=CC=C1C(=O)C1=C(C)NC(=O)N1 ZJKNESGOIKRXQY-UHFFFAOYSA-N 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
WDKXLLJDNUBYCY-UHFFFAOYSA-N ibopamine Chemical compound CNCCC1=CC=C(OC(=O)C(C)C)C(OC(=O)C(C)C)=C1 WDKXLLJDNUBYCY-UHFFFAOYSA-N 0.000 description 2
239000002571 phosphodiesterase inhibitor Substances 0.000 description 2
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
230000000391 smoking effect Effects 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
229960000984 tocofersolan Drugs 0.000 description 2
239000002076 α-tocopherol Substances 0.000 description 2
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 description 1
HPMZBILYSWLILX-UMDUKNJSSA-N 3'''-O-acetyldigitoxin Chemical compound C1[C@H](OC(C)=O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O HPMZBILYSWLILX-UMDUKNJSSA-N 0.000 description 1
HPMZBILYSWLILX-UHFFFAOYSA-N Acetyl-digitoxine Natural products C1C(OC(C)=O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O HPMZBILYSWLILX-UHFFFAOYSA-N 0.000 description 1
XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
206010007558 Cardiac failure chronic Diseases 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
NENBAISIHCWPKP-UHFFFAOYSA-N Clofenamide Chemical compound NS(=O)(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NENBAISIHCWPKP-UHFFFAOYSA-N 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
208000031309 Hypertrophic Familial Cardiomyopathy Diseases 0.000 description 1
125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
JAYAGJDXJIDEKI-UHFFFAOYSA-N Lanatoside C Natural products CC1OC(OC2CC3C(C4C(C5(CCC(C5(C)C(O)C4)C=4COC(=O)C=4)O)CC3)(C)CC2)CC(O)C1OC(OC1C)CC(O)C1OC(OC1C)CC(OC(C)=O)C1OC1OC(CO)C(O)C(O)C1O JAYAGJDXJIDEKI-UHFFFAOYSA-N 0.000 description 1
JAYAGJDXJIDEKI-PTGWOZRBSA-N Lanatoside C Chemical compound O([C@H]1[C@@H](OC(C)=O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)[C@H](O)C3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JAYAGJDXJIDEKI-PTGWOZRBSA-N 0.000 description 1
108010007859 Lisinopril Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
DOMHWKQEPDYUQX-LJAQBGIBSA-N [(2r,3r,4s,6r)-3-[(2s,4s,5r,6r)-5-[(2s,4s,5r,6r)-4,5-diformyloxy-6-methyloxan-2-yl]oxy-4-formyloxy-6-methyloxan-2-yl]oxy-6-[[(3s,5r,8r,9s,10s,13r,14s,16s,17r)-16-formyloxy-14-hydroxy-10,13-dimethyl-17-(5-oxo-2h-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17 Chemical compound C1[C@H](OC=O)[C@H](OC=O)[C@@H](C)O[C@H]1O[C@H]1[C@@H](OC=O)C[C@H](O[C@H]2[C@H](C[C@@H](O[C@@H]2C)O[C@@H]2C[C@@H]3[C@]([C@@H]4[C@H]([C@]5(C[C@@H]([C@@H]([C@@]5(C)CC4)C=4COC(=O)C=4)OC=O)O)CC3)(C)CC2)OC=O)O[C@@H]1C DOMHWKQEPDYUQX-LJAQBGIBSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
229960003635 acetyldigitoxin Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
239000000464 adrenergic agent Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
229960002576 amiloride Drugs 0.000 description 1
XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
210000002565 arteriole Anatomy 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036765 blood level Effects 0.000 description 1
229960005263 bucladesine Drugs 0.000 description 1
CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 1
210000005242 cardiac chamber Anatomy 0.000 description 1
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
229960002155 chlorothiazide Drugs 0.000 description 1
JIVPVXMEBJLZRO-UHFFFAOYSA-N chlorthalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 description 1
229960002883 clofenamide Drugs 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
OBATZBGFDSVCJD-UHFFFAOYSA-N de-O-acetyl-lanatoside C Natural products CC1OC(OC2CC3C(C4C(C5(CCC(C5(C)C(O)C4)C=4COC(=O)C=4)O)CC3)(C)CC2)CC(O)C1OC(OC1C)CC(O)C1OC(OC1C)CC(O)C1OC1OC(CO)C(O)C(O)C1O OBATZBGFDSVCJD-UHFFFAOYSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
229960005227 delapril Drugs 0.000 description 1
WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
229960001324 deslanoside Drugs 0.000 description 1
OBATZBGFDSVCJD-LALPQLPRSA-N deslanoside Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)[C@H](O)C3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OBATZBGFDSVCJD-LALPQLPRSA-N 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
229940005501 dopaminergic agent Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
ITNKVODZACVXDS-YNUSHXQLSA-N ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate Chemical compound CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC ITNKVODZACVXDS-YNUSHXQLSA-N 0.000 description 1
230000004090 etiopathogenesis Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
201000006692 familial hypertrophic cardiomyopathy Diseases 0.000 description 1
235000021323 fish oil Nutrition 0.000 description 1
229960002490 fosinopril Drugs 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
229960001486 gitoformate Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
231100000171 higher toxicity Toxicity 0.000 description 1
229960002474 hydralazine Drugs 0.000 description 1
229960004370 ibopamine Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
229960002614 lanatoside c Drugs 0.000 description 1
229960002394 lisinopril Drugs 0.000 description 1
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229960003574 milrinone Drugs 0.000 description 1
PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
230000002644 neurohormonal effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
229960002582 perindopril Drugs 0.000 description 1
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
230000036581 peripheral resistance Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229960001749 practolol Drugs 0.000 description 1
DURULFYMVIFBIR-UHFFFAOYSA-N practolol Chemical compound CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1 DURULFYMVIFBIR-UHFFFAOYSA-N 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
229960001455 quinapril Drugs 0.000 description 1
JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
229960003401 ramipril Drugs 0.000 description 1
HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
230000008085 renal dysfunction Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
229960002256 spironolactone Drugs 0.000 description 1
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
229960005461 torasemide Drugs 0.000 description 1
229960002051 trandolapril Drugs 0.000 description 1
229960001288 triamterene Drugs 0.000 description 1
229960004813 trichlormethiazide Drugs 0.000 description 1
LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
229950005577 vesnarinone Drugs 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BG108071A 2001-01-25 2003-08-07 Есенциални мастни n-3-киселини в лечението на сърдечна недостатъчност и сърдечна слабост BG108071A (bg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT2001MI000129A ITMI20010129A1 (it)	2001-01-25	2001-01-25	Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco

Publications (1)

Publication Number	Publication Date
BG108071A true BG108071A (bg)	2005-04-30

Family

ID=11446587

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108071A BG108071A (bg)	2001-01-25	2003-08-07	Есенциални мастни n-3-киселини в лечението на сърдечна недостатъчност и сърдечна слабост

Country Status (21)

Country	Link
US (3)	US20040077723A1 (no)
EP (2)	EP2258447A3 (no)
JP (1)	JP2004517148A (no)
AU (1)	AU2002225026B2 (no)
BG (1)	BG108071A (no)
CA (1)	CA2433762A1 (no)
CZ (1)	CZ20031947A3 (no)
EA (1)	EA200300830A1 (no)
EE (1)	EE05320B1 (no)
HR (1)	HRP20030561A2 (no)
HU (1)	HUP0303019A2 (no)
IS (1)	IS6862A (no)
IT (1)	ITMI20010129A1 (no)
MX (1)	MX282405B (no)
NO (1)	NO20033304D0 (no)
NZ (1)	NZ526609A (no)
PL (1)	PL363269A1 (no)
SK (1)	SK8332003A3 (no)
UA (1)	UA78693C2 (no)
WO (1)	WO2002058793A1 (no)
YU (1)	YU59303A (no)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9901809D0 (en) *	1999-01-27	1999-03-17	Scarista Limited	Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
ITMI20010129A1 (it) *	2001-01-25	2002-07-25	Pharmacia & Upjohn Spa	Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
ITMI20012384A1 (it)	2001-11-12	2003-05-12	Quatex Nv	Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
ITMI20020269A1 (it) *	2002-02-12	2003-08-12	Victorix Assets Ltd	Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
US20060289834A1 (en) *	2002-11-22	2006-12-28	Nobushige Doisaki	External composition containing Unsaturated fatty acid or its salt or ester
ITMI20022511A1 (it) *	2002-11-26	2004-05-27	Victorix Assets Ltd	Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
PL1611088T3 (pl) *	2003-04-07	2009-11-30	Pharmacyclics Inc	Hydroksamiany jako środki terapeutyczne
WO2004091603A1 (fr) *	2003-04-07	2004-10-28	Clinigenetics	Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires
SE0303513D0 (sv) *	2003-12-19	2003-12-19	Pronova Biocare As	Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
EP1750862B1 (en)	2004-06-04	2011-01-05	Teva Pharmaceutical Industries Ltd.	Pharmaceutical composition containing irbesartan
EP1865770A4 (en) *	2005-04-07	2010-12-29	Nitromed Inc	ASSESSMENT OF GENETIC RISK IN CARDIAC ERRORS: IMPACT OF THE GENETIC VARIATION OF NOS3
FR2902659A1 (fr) *	2006-06-23	2007-12-28	Pierre Fabre Medicament Sa	Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
CA2692394A1 (en) *	2007-07-06	2009-01-15	Seth J. Baum	Fatty acid compositions and methods of use
US9468668B2 (en)	2011-08-11	2016-10-18	Allergy Research Group, Llc	Flavored chewable lipid supplements for maintaining health and the treatment of acute and chronic disorders
US8877239B2 (en)	2010-08-12	2014-11-04	Nutritional Therapeutics, Inc.	Lipid supplements for maintaining health and treatment of acute and chronic disorders
US8343753B2 (en)	2007-11-01	2013-01-01	Wake Forest University School Of Medicine	Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP2323647B1 (en)	2008-08-07	2014-09-10	SPA SOCIETA' PRODOTTI ANTIBIOTICI S.p.A.	Long-term treatment of symptomatic heart failure
WO2010018856A1 (ja) *	2008-08-13	2010-02-18	持田製薬株式会社	カンナビノイド受容体関連疾患の予防／改善または治療剤
US20110236476A1 (en)	2008-09-02	2011-09-29	Amarin Corporation Plc.	Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
PT3037089T (pt)	2009-02-10	2020-03-04	Amarin Pharmaceuticals Ie Ltd	Ester etílico de ácido eicosapentaenoico para tratamento de hipertrigliceridemia
WO2010118362A1 (en)	2009-04-09	2010-10-14	The Regents Of The University Of Colorado, A Body Corporate	Methods and compositions for inducing physiological hypertrophy
WO2010127099A2 (en)	2009-04-29	2010-11-04	Amarin Corporation Plc	Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SG10201605794PA (en)	2009-04-29	2016-09-29	Amarin Pharmaceuticals Ie Ltd	Stable Pharmaceutical Composition And Methods Of Using Same
CN108096209A (zh)	2009-06-15	2018-06-01	阿马里纳制药公司	在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
WO2011038122A1 (en)	2009-09-23	2011-03-31	Amarin Corporation Plc	Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
RU2606853C2 (ru) *	2010-03-04	2017-01-10	Амарин Фармасьютикалз Айрлэнд Лимитед (Апил)	Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания
EP2646013A4 (en)	2010-11-29	2014-03-26	Amarin Pharma Inc	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2674157A4 (en) *	2011-02-07	2014-07-09	Mochida Pharm Co Ltd	THERAPEUTIC AGENT FOR CONGESTIVE DIASTOLIC HEART INSUFFICIENCY
US9119826B2 (en)	2011-02-16	2015-09-01	Pivotal Therapeutics, Inc.	Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8952000B2 (en)	2011-02-16	2015-02-10	Pivotal Therapeutics Inc.	Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en)	2011-02-16	2015-02-10	Pivotal Therapeutics Inc.	Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8715648B2 (en)	2011-02-16	2014-05-06	Pivotal Therapeutics Inc.	Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US11253531B2 (en)	2011-08-11	2022-02-22	Nutritional Therapeutics, Inc.	Lipid supplements for reducing nerve action potentials
US10117885B2 (en)	2011-08-11	2018-11-06	Allergy Research Group, Llc	Chewable lipid supplements for treating pain and fibromyalgia
EP2775837A4 (en)	2011-11-07	2015-10-28	Amarin Pharmaceuticals Ie Ltd	METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
JP6307442B2 (ja)	2012-01-06	2018-04-04	アマリンファーマシューティカルスアイルランドリミテッド	対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
SMT202500326T1 (it)	2012-06-29	2025-11-10	Amarin Pharmaceuticals Ie Ltd	Estere etilico dell’acido eicosapentaenoico per l’uso nella riduzione del rischio di ictus non fatale in un soggetto in terapia con statine
US20150265566A1 (en)	2012-11-06	2015-09-24	Amarin Pharmaceuticals Ireland Limited	Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en)	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
WO2014110451A1 (en)	2013-01-10	2014-07-17	Nutritional Therapeutics, Inc.	Chewable wafers containing lipid supplements for maintaining health and the treatment of acute and chronic disorders
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)	2013-02-19	2017-05-30	The Regents Of The University Of Colorado	Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
WO2015195662A1 (en)	2014-06-16	2015-12-23	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en)	2017-05-19	2018-11-22	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
EP3700518A4 (en)	2018-09-24	2020-12-16	Amarin Pharmaceuticals Ireland Limited	METHODS OF REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT
CN114980973A (zh)	2019-11-12	2022-08-30	阿马里纳药物爱尔兰有限公司	降低心房纤颤和/或心房扑动受试者心血管事件风险的方法
EP4326244A4 (en)	2021-04-21	2025-03-19	Amarin Pharmaceuticals Ireland Limited	METHODS TO REDUCE THE RISK OF HEART FAILURE

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5735512A (en)	1980-06-27	1982-02-26	Nippon Oil & Fats Co Ltd	Preventive and remedy for thrombosis
NO157302C (no)	1985-12-19	1988-02-24	Norsk Hydro As	Fremgangsmaate for fremstilling av et fiskeoljekonsentrat.
US4920098A (en) *	1986-09-17	1990-04-24	Baxter International Inc.	Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
IT1205043B (it)	1987-05-28	1989-03-10	Innova Di Ridolfi Flora & C S	Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
GB2218984B (en) *	1988-05-27	1992-09-23	Renafield Limited	Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
DD273852B3 (de)	1988-07-07	1993-01-21	Zentralinstitut Fuer Ernaehrun	Verfahren zur gewinnung und aufkonzentrierung polyenfettsaeurereicher lipide
GB8819110D0 (en)	1988-08-11	1988-09-14	Norsk Hydro As	Antihypertensive drug & method for production
US6140304A (en)	1988-09-28	2000-10-31	Eicotech Corporation	Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia
JP3103588B2 (ja)	1990-11-16	2000-10-30	持田製薬株式会社	リポプロテイン（ａ）低下剤
US5324323A (en) *	1992-09-09	1994-06-28	Telectronics Pacing Systems, Inc.	Multiple channel cardiosynchronous myoplasty apparatus
US5208236A (en) *	1992-09-23	1993-05-04	Schering Corporation	N-(acylaminomethyl)glutaryl amino acids and use
JPH08506097A (ja) *	1992-12-11	1996-07-02	チバ−ガイギーアクチェンゲゼルシャフト	置換されたベンズアゼピノン
CN1082909A (zh)	1993-01-03	1994-03-02	潘玉珍	精制二十二碳六烯酸乙酯复合溶栓、抗痴呆药剂
JPH06263634A (ja)	1993-03-10	1994-09-20	Sagami Chem Res Center	カルシウム拮抗薬
JPH07118229A (ja) *	1993-10-19	1995-05-09	Fujisawa Pharmaceut Co Ltd	尿素誘導体およびその製造法
US5760081A (en) *	1994-05-10	1998-06-02	The General Hospital Corporation	Omega 3 fatty acids in the prevention of ventricular fibrillation
JPH0812581A (ja) *	1994-06-30	1996-01-16	Fujirebio Inc	虚血性心疾患治療剤
JPH0853350A (ja)	1994-08-11	1996-02-27	Sagami Chem Res Center	抗肺水腫薬
IT1274734B (it) *	1994-08-25	1997-07-24	Prospa Bv	Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
JPH08151334A (ja)	1994-11-25	1996-06-11	Sagami Chem Res Center	リポソームおよびその製剤
GB9506837D0 (en)	1995-04-03	1995-05-24	Scotia Holdings Plc	Triglycerides
MY118354A (en)	1995-05-01	2004-10-30	Scarista Ltd	1,3-propane diol derivatives as bioactive compounds
DK0760393T3 (da)	1995-08-17	2003-09-29	Hoffmann La Roche	Kromatografifremgangsmåde
IT1277953B1 (it)	1995-12-21	1997-11-12	Sigma Tau Ind Farmaceuti	Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
US6333447B1 (en) *	1996-03-29	2001-12-25	The General Hospital Corporation	Transgenic model of heart failure
US5861399A (en) *	1996-07-17	1999-01-19	Heart Care Partners	Methods and compositions for the rapid and enduring relief of inadequate myocardial function
AU741931B2 (en) *	1996-09-05	2001-12-13	Collateral Therapeutics, Inc.	Gene therapy for congestive heart failure
EP1004303B1 (en) *	1997-06-16	2004-10-13	Nippon Suisan Kaisha, Ltd.	Composition having capability of removing risk factor during exercise
SK285863B6 (sk) *	1998-07-10	2007-10-04	Novartis Ag	Kombinovaná farmaceutická kompozícia obsahujúca AT1-antagonistu valsartan a amlodipín
IT1308613B1 (it) *	1999-02-17	2002-01-09	Pharmacia & Upjohn Spa	Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
GB9916536D0 (en)	1999-07-14	1999-09-15	Scarista Limited	Nutritional or pharmaceutical compositions
ES2159257B1 (es)	1999-11-19	2002-04-16	Kd Iqa S L	Nuevo procedimiento de preparacion del ester etilico del acido eicosa pentaenoico.
CA2291959A1 (en)	1999-12-08	2001-06-08	Alex P. Korn	A nutriceutical composition of l-carnitine, ubiquinone, n-3 polyunsaturated fatty acids and vitamins specifically formulated at pharmacological doses for the amelioration of the risk factors and symptoms of atherosclerosis-related illnesses
US8753675B1 (en)	2000-01-20	2014-06-17	Raj K. Chopra	Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
IL151299A0 (en)	2000-02-16	2003-04-10	Brigham & Womens Hospital	Aspirin-triggered lipid mediators
EP1130027A1 (de) *	2000-02-29	2001-09-05	Aventis Pharma Deutschland GmbH	Memno-Peptide, Verfahren zu ihrer Herstellung und Verwendung derselben
JP4139544B2 (ja)	2000-03-06	2008-08-27	花王株式会社	血糖値低下剤
CA2304906A1 (en)	2000-04-07	2001-10-07	1411198 Ontario Limited	13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
ATE305810T1 (de)	2000-05-22	2005-10-15	Pro Aparts Investimentos E Con	Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält
GB0016045D0 (en)	2000-06-29	2000-08-23	Laxdale Limited	Therapeutic combinations of fatty acids
DE10056351A1 (de)	2000-11-14	2002-05-29	Weylandt Karsten Henrich	Pharmazeutisches Präparat
ITMI20010129A1 (it) *	2001-01-25	2002-07-25	Pharmacia & Upjohn Spa	Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco

2001
- 2001-01-25 IT IT2001MI000129A patent/ITMI20010129A1/it unknown
2002
- 2002-01-16 HU HU0303019A patent/HUP0303019A2/hu unknown
- 2002-01-16 MX MXPA03006480 patent/MX282405B/es active IP Right Grant
- 2002-01-16 HR HR20030561A patent/HRP20030561A2/hr not_active Application Discontinuation
- 2002-01-16 JP JP2002559123A patent/JP2004517148A/ja active Pending
- 2002-01-16 AU AU2002225026A patent/AU2002225026B2/en not_active Ceased
- 2002-01-16 EE EEP200300297A patent/EE05320B1/xx not_active IP Right Cessation
- 2002-01-16 YU YU59303A patent/YU59303A/sh unknown
- 2002-01-16 EP EP10183221A patent/EP2258447A3/en not_active Withdrawn
- 2002-01-16 NZ NZ526609A patent/NZ526609A/en not_active IP Right Cessation
- 2002-01-16 PL PL02363269A patent/PL363269A1/xx not_active Application Discontinuation
- 2002-01-16 EP EP02715455A patent/EP1365841A1/en not_active Ceased
- 2002-01-16 EA EA200300830A patent/EA200300830A1/ru unknown
- 2002-01-16 WO PCT/EP2002/000507 patent/WO2002058793A1/en not_active Ceased
- 2002-01-16 CZ CZ20031947A patent/CZ20031947A3/cs unknown
- 2002-01-16 CA CA002433762A patent/CA2433762A1/en not_active Abandoned
- 2002-01-16 UA UA2003087938A patent/UA78693C2/uk unknown
- 2002-01-16 US US10/451,623 patent/US20040077723A1/en not_active Abandoned
- 2002-01-16 SK SK833-2003A patent/SK8332003A3/sk not_active Application Discontinuation
2003
- 2003-06-27 IS IS6862A patent/IS6862A/is unknown
- 2003-07-22 NO NO20033304A patent/NO20033304D0/no not_active Application Discontinuation
- 2003-08-07 BG BG108071A patent/BG108071A/bg unknown
2006
- 2006-01-17 US US11/333,387 patent/US7439267B2/en not_active Expired - Fee Related
2008
- 2008-09-09 US US12/207,068 patent/US20090005327A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2002225026B2 (en)	2007-09-13
US7439267B2 (en)	2008-10-21
HUP0303019A2 (hu)	2003-12-29
CA2433762A1 (en)	2002-08-01
EE200300297A (et)	2003-10-15
EP2258447A2 (en)	2010-12-08
EP1365841A1 (en)	2003-12-03
HRP20030561A2 (en)	2005-06-30
SK8332003A3 (en)	2003-11-04
EE05320B1 (et)	2010-08-16
UA78693C2 (en)	2007-04-25
US20040077723A1 (en)	2004-04-22
EP2258447A3 (en)	2012-07-25
JP2004517148A (ja)	2004-06-10
NZ526609A (en)	2005-10-28
WO2002058793A1 (en)	2002-08-01
CZ20031947A3 (cs)	2003-12-17
NO20033304L (no)	2003-07-22
EA200300830A1 (ru)	2003-12-25
IS6862A (is)	2003-06-27
MXPA03006480A (es)	2003-09-22
PL363269A1 (en)	2004-11-15
MX282405B (es)	2010-12-21
ITMI20010129A1 (it)	2002-07-25
NO20033304D0 (no)	2003-07-22
YU59303A (sh)	2006-08-17
US20060205814A1 (en)	2006-09-14
US20090005327A1 (en)	2009-01-01

Publication	Publication Date	Title
BG108071A (bg)	2005-04-30	Есенциални мастни n-3-киселини в лечението на сърдечна недостатъчност и сърдечна слабост
AU2002225026A1 (en)	2003-02-06	Essential N-3 fatty acids in cardiac insufficiency and heart failure therapy
JP5441287B2 (ja)	2014-03-12	心血管事象を予防するための必須脂肪酸
KR102488648B1 (ko)	2023-01-12	ω3 지방산의 자기 유화 조성물
KR101336756B1 (ko)	2013-12-04	뇌졸중 재발 예방용 조성물
KR20080024511A (ko)	2008-03-18	심혈관 이벤트 발병 예방용 조성물
HK1202795A1 (en)	2015-10-09	Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP3023098A1 (en)	2016-05-25	Self-emulsifying composition of -3 fatty acid
WO1995017889A1 (en)	1995-07-06	Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis
KR20010040776A (ko)	2001-05-15	염증 상태의 치료방법 및 이를 위한 조성물
RS59303B1 (sr)	2019-10-31	Spojnica
JP5226980B2 (ja)	2013-07-03	ＨＭＧ−ＣｏＡリダクターゼ阻害剤、トコフェロール類及びＣｏＱ１０を含有する医薬組成物
EA020237B1 (ru)	2014-09-30	Способ снижения смертности от сердечно-сосудистых событий
US20080014187A1 (en)	2008-01-17	Compositions and Methods for Treating Hypertension and Inflammation
WO2001085155A1 (en)	2001-11-15	Method and compositions for inhibiting arteriosclerosis
RU2387448C2 (ru)	2010-04-27	Незаменимые жирные кислоты, предназначенные для предупреждения и/или лечения депрессии у пациентов, страдающих коронарной болезнью сердца или болезнью коронарной артерии
CN1481239A (zh)	2004-03-10	血中脂类改善剂组合物
JP2007532605A5 (no)	2012-01-26
JPS6011422A (ja)	1985-01-21	抗筋ジストロフイ−症剤
ITMI20101070A1 (it)	2011-12-15	Uso di composizioni di acidi grassi polinsaturi selezionati per il trattamento dello scompenso cardiaco diastolico.
JP2013032400A (ja)	2013-02-14	ＨＭＧ−ＣｏＡリダクターゼ阻害剤、トコフェロール類及びＣｏＱ１０を含有する医薬組成物２